Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



A Ringing Endorsement of a Technology Years in the Making

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Biogen Idec (NASDAQ: BIIB  ) is going back to the antisense well, teaming up with¬†Isis Pharmaceuticals (NASDAQ: IONS  ) for the fourth time in two years.

Endorsements of a technology don't get bigger than that.

For the latest deal, Biogen is giving Isis $100 million up front, and Isis is eligible to receive as much as $220 million per drug developed through the new collaboration. Isis would also collect royalties on the drugs if they make it to the market.

Unlike the earlier collaborations on spinal muscular atrophy, myotonic dystrophy type 1, and a third that covered three novel targets for neurological disorders, this partnership is an earlier development-stage deal.

The companies will start with basic research to identify new targets for different neurological disorders; on the conference call, Isis and Biogen cited amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, as one of the potential diseases.

Isis and Biogen think they can identify two or more targets a year. Not all of them are going to work out, but even one drug a year would be a pretty impressive partnership.

Molecular switch
The attraction of Isis' antisense technology lies in its simplicity. Antisense works by inhibiting the production of a specific protein. Essentially it can turn a specific gene off by acting on the RNA molecule that is the intermediary between the gene and the protein it encodes for.

All you need to do is find a protein that improves disease symptoms when its expression is knocked down. Designing an antisense molecule to bind to the RNA is typically much easier than creating a drug that can inhibit the protein's function.

Isis isn't the only one using this approach. Alnylam Pharmaceuticals (NASDAQ: ALNY  ) has a related technology called RNAi that acts on the RNA intermediary, degrading it through another mechanism. Biogen has a partnership with Alnylam as well, so it clearly likes the strategy.

But Isis is the leader in the field, mostly because it's been doing it for so long; Isis was founded in 1988!

While the idea of antisense is simple, the development of the technology has been challenging, mostly because the drugs weren't particularly stable. Fortunately, Isis seems to have solved the problem with next-generation technology, highlighted by its recently approved drug Kynamro.

Best drug for the job
Admittedly, there are other ways to treat diseases other than lowering protein expression; small molecules and antibodies can inhibit the protein's function by binding to it. Interestingly the Biogen-Isis partnership allows for the companies to determine the best way to target the proteins they discover. If an approach other than antisense is most feasible, Biogen will take over development and Isis will get a smaller royalty for its early discovery effort on that drug.

Isis is up 200% year to date. If you're looking for more ideas for companies with that kind of growth potential you should check out, Motley Fool co-founder David Gardner's unique strategy for uncovering truly wealth-changing stock picks. He wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2630910, ~/Articles/ArticleHandler.aspx, 9/25/2016 12:15:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
ALNY $75.57 Down -1.52 -1.97%
Alnylam Pharmaceut… CAPS Rating: ****
BIIB $312.58 Down -2.23 -0.71%
Biogen CAPS Rating: *****
IONS $35.12 Up +0.10 +0.29%
Ionis Pharmaceutic… CAPS Rating: *****